Commercializing Protein Tomography Solutions

Based on current practices, protein tomography is estimated to be a U.S.$200 million market with the potential to grow several-fold within a few years.

Protein tomography was developed for studying the molecular nature of disease pathways and for validating preclinical models and investigating the activity of candidate therapeutics. Protein tomography makes it possible to visualize biomolecules in situ, even in a cell membrane. FEI has developed cryo-electron microscopy for the imaging of biologic structures in collaboration with academic groups in Europe and the United States. Sidec is developing protein imaging using cryo-electron microscopy, and has research collaborations with global pharmaceutical companies.

Advanced electron microscopy instrumentation, data acquisition, and reconstruction software that enable the imaging and analysis of individual protein molecules in cells and tissues are being offered by FEI and Sidec. The service is being provided through Sidec, as an on-premises service or through software and other intellectual property license arrangements, combined with a TEM sale.


Related Links:
Sidec
FEI